CompletedNot Applicable

Evaluation of Fluid Biomarkers Around Implants Exhibiting Early Stage Periimplant Bone Loss

Turkey (Türkiye)59 participantsStarted 2025-03-06

Plain-language summary

This study aimed to compare biological mediators known to be important in peri-implant diseases in implants with and without early stage marginal bone loss. A total of 118 implants in 59 patients were designated as test and control groups. The radiographic and periodontal data of the included implants, along with peri-implant sulcus fluid samples, were evaluated.

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Presence of 1 mm or more of radiographic marginal bone loss within the first 3 months after implant placement * Availability of radiographic documentation * Availability of demographic data, surgical records, and data related to the implant used * Physical condition classified as Class I and II according to the American Society of Anesthesiologists (ASA) classification * Patients with no smoking history in the last 10 years * Fixed implant-supported restorations * Screw-retained implants Exclusion Criteria: * Patients receiving and/or maintaining implant treatment at centers other than the Department of Periodontology, Pamukkale University Faculty of Dentistry * Patients with incomplete or unreachable files or radiographic documentation * Patients with a known systemic disease/condition that alters their physical condition or bone metabolism * Severe bruxism cases * Pregnant and breastfeeding patients * Patients with incomplete implant-supported prosthesis * Areas grafted during or before implant surgery * Removable implant-supported restorations * Cement-retained implants * Patients undergoing peri-implantitis treatment

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Calprotectin levels in peri-implant crevicular fluid

Timeframe: 6-8 week after prosthetic treatment

Sclerostin levels in peri-implant crevicular fluid

Timeframe: 6-8 week after prosthetic treatment

NTx levels in peri-implant crevicular fluid

Timeframe: 6-8 week after prosthetic treatment

MMP-8 levels in peri-implant crevicular fluid

Timeframe: 6-8 week after prosthetic treatment

MMP-9 levels in peri-implant crevicular fluid

Timeframe: 6-8 week after prosthetic treatment

Trial details

NCT IDNCT07584759

SponsorPamukkale University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-09-06

View on ClinicalTrials.gov More Peri-implant Bone Loss trials

Plain-language summary

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Calprotectin levels in peri-implant crevicular fluid

Timeframe: 6-8 week after prosthetic treatment

Sclerostin levels in peri-implant crevicular fluid

Timeframe: 6-8 week after prosthetic treatment

NTx levels in peri-implant crevicular fluid

Timeframe: 6-8 week after prosthetic treatment

MMP-8 levels in peri-implant crevicular fluid

Timeframe: 6-8 week after prosthetic treatment

MMP-9 levels in peri-implant crevicular fluid

Timeframe: 6-8 week after prosthetic treatment